Shanghai Fosun Pharmaceutical (02196) subsidiary's drug has been granted clinical trial approval.

Shanghai Fosun Pharmaceutical (02196) issued an announcement that its holding subsidiary Shanghai HENLIUS Biotechnology Co., Ltd. and its holding subsidiary (collectively "HENLIUS") have received approval from the National Medical Products Administration to conduct Phase I clinical trials of HLX97 (i.e. KAT6A/B small molecule inhibitor) for the treatment of advanced/metastatic solid tumors. HENLIUS plans to conduct related clinical studies of the drug in China once the conditions are met. HLX97 is a small molecule inhibitor of lysine acetyltransferase 6A/B (KAT6A/B) independently developed by the group, intended for the treatment of advanced/metastatic solid tumors. As of January 2026, the group's cumulative research and development investment for HLX97 is approximately RMB 17.55 million (unaudited). As of the date of this announcement (March 5, 2026), there are no approved KAT6A/B small molecule inhibitors marketed globally.